



# LanthaScreen® TR-FRET Pregnane X Receptor Competitive Binding Assay

Catalog no. PV4839

Shipping: Dry Ice

Initial Storage: Varies

Protocol part no. PV4839.pps

Rev. date: 11 February 2010

## Table of Contents

<b>1. Kit Contents</b>	<b>2</b>
<b>2. Materials Required but Not Supplied</b>	<b>2</b>
<b>3. Introduction</b>	<b>3</b>
3.1 Principle of FRET and TR-FRET	3
3.2 Assay Overview	3
<b>4. Instrument Settings</b>	<b>4</b>
4.1 General Considerations	4
4.2 General Settings for Filter-based instruments:	5
4.3 General Settings for Monochromator-based Instruments	6
4.4 General Settings for CCD-based instruments:	6
<b>5. Guidelines and Recommendations</b>	<b>6</b>
5.1 Reagent Handling	6
5.2 Ligand Dilutions	7
5.3 Solvent Tolerance	7
5.4 Reagent Order of Addition	7
5.5 Incubation Conditions	8
<b>6. Procedure</b>	<b>8</b>
6.1 Assay Set-Up	8
6.2 Plate Layout	10
6.3 Data Analysis	10
6.4 Reagent Volumes and Controls	11
<b>7. Assay Pharmacology</b>	<b>12</b>
<b>8. References</b>	<b>13</b>
<b>9. Notice to Purchaser</b>	<b>13</b>

For Technical Support for this or other Drug Discovery Products, dial 760-603-7200 extension 40266

For information on frequently asked questions regarding the LanthaScreen® technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)

## 1. Kit Contents

The LanthaScreen® TR-FRET PXR (SXR) Competitive Binding Assay kit, catalog no. PV4839, contains the following:

Component	Composition	Amount	Storage Temp.	Individual Catalog No.
Fluormone™ PXR (SXR) Green	4 µM in 50% methanol/water	200 µL	-80°C	PV4843
PXR-LBD (GST)	Human PXR ligand-binding domain in buffer (pH 8.0) containing protein stabilizing reagents and glycerol. See Certificate of Analysis for lot-specific concentration.	10 µg	-80°C	PV4840
LanthaScreen™ Tb-anti-GST antibody	Terbium-labeled anti-GST antibody in HEPES buffered saline (137 mM NaCl, 2.7 mM KCl, 10 mM HEPES pH 7.5). See Certificate of Analysis for lot specific concentration.	25 µg	-20°C	PV3550
TR-FRET PXR (SXR) Assay Buffer	Proprietary buffer (pH 7.5).	25 mL	Room temperature	PV4842
DTT, 1 M	In water.	1 mL	-20°C or -80°C	P2325

## 2. Materials Required but Not Supplied

The following materials are required but not supplied in the kit:

- A fluorescence plate reader with excitation capabilities at 340 nm and with the appropriate filter sets installed for detecting the fluorescent emission signals of terbium at 495 nm and fluorescein at 520 nm (see **Section 4**).
- Pipetting devices for 1–1000 µL volumes, suitable repeater pipettors, or multi-channel pipettor.
- Black, 384-well assay plates. We recommend black Corning® 384-well, low-volume, round-bottom, black (non-treated surface) assay plates, catalog # 3677. Other plate types may give satisfactory results as well but have not been fully tested.

**Note:** We previously recommended polypropylene plates (*e.g.*, MatriCal #MP101-1-PP), but further testing has shown that lot-to-lot variability in the plates negatively impacts the Z' factor of the assay.

- 96-well polypropylene plates that can accommodate a 300-µL volume per well for the ligand serial dilutions in 100% DMSO. Polypropylene plates are needed since they are tolerant to DMSO. We recommend Nalgen® Nunc™ #249944.
- A known PXR ligand to serve as a positive control. We recommend SR-12813 (Biomol cat. no. GR242).
- DMSO to perform serial dilutions. We recommend Fluka 41647.

**For Technical Support for this or other Drug Discovery Products, dial 760-603-7200 extension 40266**

For information on frequently asked questions regarding the LanthaScreen® technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)

## 3. Introduction

The LanthaScreen® TR-FRET PXR (SXR) Competitive Binding Assay provides a sensitive and robust method for high-throughput screening of ligands for PXR (SXR). The kit uses a terbium-labeled anti-GST antibody, a fluorescent small molecule PXR ligand (Fluormone™ PXR (SXR) Green, also referred to as “tracer”), and a human PXR ligand-binding domain that is tagged with glutathione-S-transferase (GST) in a homogenous mix-and-read assay format. This kit contains enough reagents for 800 assays of 20 µL each.

### 3.1 Principle of FRET and TR-FRET

For screening libraries of compounds, time-resolved FRET (TR-FRET) is a recognized method for overcoming interference from compound autofluorescence or light scatter from precipitated compounds. The premise of a TR-FRET assay is the same as that of a standard FRET assay: when a suitable pair of fluorophores is brought within close proximity of one another, excitation of the first fluorophore (the donor) can result in energy transfer to the second fluorophore (the acceptor). This energy transfer is detected by an increase in the fluorescence emission of the acceptor and a decrease in the fluorescence emission of the donor. In HTS assays, FRET is often expressed as a ratio of the intensities of the acceptor and donor fluorophores. The ratiometric nature of such a value corrects for differences in assay volumes between wells and corrects for quenching effects due to colored compounds.

In contrast to standard FRET assays, TR-FRET assays use a long-lifetime lanthanide chelate as the donor species. Lanthanide chelates are unique in that their excited-state lifetime (the average time that the molecule spends in the excited state after accepting a photon) can be on the order of a millisecond or longer. This is in sharp contrast to the lifetime of common fluorophores used in standard FRET assays, which are typically in the nanosecond range. Because interference from autofluorescent compounds or scattered light from precipitated compounds is also on the nanosecond timescale, these factors can negatively impact standard FRET assays. To overcome these interferences, TR-FRET assays are performed by measuring FRET after a suitable delay, typically 100 microseconds after excitation by a flashlamp excitation source in a microtiter plate reader. This delay not only overcomes interference from background fluorescence or light scatter, but also avoids interference from direct excitation due to the non-instantaneous nature of the flashlamp excitation source.

The most common lanthanides used in TR-FRET assays for HTS are terbium (Tb) and europium (Eu). Terbium offers unique advantages over europium when used as the donor species in a TR-FRET assay. In contrast to europium-based systems that employ the relatively large protein APC as the acceptor, terbium-based TR-FRET assays can use common small molecule fluorophores such as fluorescein as the acceptor. It is straightforward (and inexpensive) to directly label a molecule such as a peptide with fluorescein for use in terbium-based TR-FRET assays. In addition, the assay format is simpler than using a biotinylated peptide that would then be indirectly labeled via streptavidin-mediated recruitment of APC. Therefore, the use of directly labeled molecules (in this case the fluorescent ligand) in a terbium-based TR-FRET assay simplifies assay development by reducing the number of components to optimize, avoids problems due to steric interactions involving large APC conjugates, reduces costs, and improves kinetics.

### 3.2 Assay Overview

A terbium-labeled anti-GST antibody is used to indirectly label a nuclear receptor (NR) by binding to its GST tag. Competitive binding to the NR is detected by a test compound's ability to displace a fluorescent ligand (tracer) from the NR, which results in a loss of FRET signal between the Tb-anti-GST antibody and the tracer. This type of binding assay is analogous to radioligand-based assays, except that it eliminates handling of radioactivity and enables a homogenous, “addition-only” format.


When running the LanthaScreen® TR-FRET PXR (SXR) Competitive Binding Assay, Fluormone™ PXR (SXR) Green tracer is added to ligand test compounds or solvent controls followed by addition of a mixture of the PXR-LBD and terbium anti-GST antibody. After an incubation period at room temperature, the TR-FRET ratio of 520:495 emissions is calculated and can be used to determine the IC<sub>50</sub> from a dose response curve of the compound.

The recommended concentration of PXR-LBD (GST) and Tb anti-GST antibody have been optimized to produce a satisfactory assay window ( $Z' > 0.5$ ) while using the lowest receptor concentration to achieve the best sensitivity

For Technical Support for this or other Drug Discovery Products, dial 760-603-7200 extension 40266

For information on frequently asked questions regarding the LanthaScreen® technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)

to tight binding ligands. The assay window is highly dependent on the sensitivity of the fluorescent plate reader. Different plate readers may provide different assay windows and  $Z'$  factors. These assays were optimized using a BMG LABTECH PHERAstar fluorescent plate reader, which is considered very sensitive for these assays. If the assay window is not acceptable on your instrument, additional receptor or receptor and antibody may be added. Please note that this will decrease the sensitivity of the assay to tight binders.



**Figure 1. Principle of a LanthaScreen® TR-FRET NR Competitive Binding assay:** Tb-anti-GST antibody indirectly labels the nuclear receptor by binding to the GST tag. Binding of the fluorescently labeled tracer results in close proximity of the tracer to the terbium-labeled antibody, resulting in a high TR-FRET signal. When competitor displaces the fluorescently labeled tracer, there is a decrease in the TR-FRET signal.

## 4. Instrument Settings

The LanthaScreen® Tb Instrument Control Kit, PV5591, has been included to facilitate instrument set-up. We recommend that you use this kit to verify your instrument settings before proceeding with any Nuclear Receptor Biology. For additional help in setting up your instrument to perform LanthaScreen® TR-FRET assays, please contact Invitrogen Drug Discovery technical support at 800-955-6288 (select option 3 and enter 40266), or email [drugdiscoverytech@invitrogen.com](mailto:drugdiscoverytech@invitrogen.com). Please see [www.invitrogen.com/instrumentsetup](http://www.invitrogen.com/instrumentsetup) for instrument specific information, including step-by-step instrument specific guides for optimizing LanthaScreen® Terbium assays on your particular instrument.

The LanthaScreen® technology has been tested on a variety of microplate readers. These include filter-based instruments, Tecan ULTRA, GENiosPro, and Infinite® F500, BMG LABTECH PHERAstar; BioTek Instruments Synergy™ 2 and Synergy™ 4; PerkinElmer EnVision® and VICTOR™, and MDS Analytical Technologies Analyst®. CCD-based imagers (PerkinElmer ViewLux™) and monochromator-based instruments (Tecan Safire2™ and Infinite® M1000).


### 4.1 General Considerations

The excitation and emission spectra of terbium and fluorescein are shown in Figure 2. To read a LanthaScreen® TR-FRET assay, the instrument is configured to excite the terbium donor around 340 nm, and to separately read the terbium emission peak that is centered at approximately 490 nm, and the fluorescein emission that is centered at approximately 520 nm. Separation of the terbium emission signal from the fluorescein emission signal is critical for assay success and is achieved with the proper selection of filter bandwidths which cannot be compromised. For this reason a standard fluorescein filter cannot typically be used. After taking the measurements, the signal from the fluorescein emission is divided (or "ratioed") by the terbium signal to provide a TR-FRET emission ratio and improve the  $Z'$  for the assay.

For Technical Support for this or other Drug Discovery Products, dial 760-603-7200 extension 40266

For information on frequently asked questions regarding the LanthaScreen® technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)

## Spectra of Terbium and Fluorescein



**Figure 2.** Excitation and emission spectra of fluorescein and terbium.

Aside from filter choices, other instrument settings are similar to the settings used with europium-based technologies. A delay time of 100  $\mu$ s followed by a 200- $\mu$ s integration time is typical for a LanthaScreen® TR-FRET assay. The number of flashes or measurements per well is highly instrument dependent and should be set as advised by your instrument manufacturer.

### 4.2 General Settings for Filter-based instruments:

<b>Excitation</b>	340 nm filter (30 nm bandwidth)
<b>Fluorescein Emission</b>	520 nm filter (25 nm bandwidth)
<b>Terbium Emission</b>	490 or 495 nm filter (10 nm bandwidth)
<b>Dichroic Mirror</b>	Fluorescein (Tecan ULTRA, GENios, GENios Pro, Infinite®) PerkinElmer LANCE®/TRF (EnVision®, VICTOR™) 380 nm (preferred) or 400 nm (MDS Analytical Technologies Analyst®) Built In (BMG LABTECH PHERAstar)
<b>Delay Time</b>	100 $\mu$ s
<b>Integration Time</b>	200 $\mu$ s

Note that excitation filters with similar bandwidths will give satisfactory performance as long as the center wavelength falls at or between 330 nm and 340 nm. Excitation and emission filters (from Chroma Technologies) for most microplate readers are available directly from Invitrogen. Visit [www.invitrogen.com/instrumentsetup](http://www.invitrogen.com/instrumentsetup) to identify filters for your instrument. A LanthaScreen® Tb filter optical module is available directly from BMG LABTECH for use on the PHERAstar. PerkinElmer Envision® users may require a specific filter holder which is available from PerkinElmer as part # 2100-8110 for a package of 10.

**For Technical Support for this or other Drug Discovery Products, dial 760-603-7200 extension 40266**

For information on frequently asked questions regarding the LanthaScreen® technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)

### 4.3 General Settings for Monochromator-based Instruments

Excitation	332 nm (20 nm bandwidth)
Fluorescein Emission	515 nm (20 nm bandwidth)
Terbium Emission	486 nm (20 nm bandwidth)
Delay Time	100 $\mu$ s
Integration Time	200 $\mu$ s

Some monochromator-based instruments, such as the Tecan Infinite® M1000, allow each emission wavelength to be individually set. In this case, match the settings to those listed for the filter-based instruments. When the bandwidths of the two emission wavelengths cannot be individually set, use the general settings for monochromator-based instruments listed in the table above as a guide.

Note that not all monochromator-based instruments are capable of a 20-nm bandwidth. Smaller bandwidth settings may be used, but with a decrease in assay performance. Additionally, we have found that while some monochromator based instruments (Tecan Safire<sup>2</sup>™, Tecan Infinite® M1000) give satisfactory performance in LanthaScreen® TR-FRET assays, other monochromator-based instruments (e.g. Tecan Safire™ and MDS Analytical Technologies Gemini and SpectraMax® M2 and M5) may not be optimal for detection, although some change in signal and a ratio may still be observed. We have also found that with some assays, white plates give better assay performance when using monochromator-based instruments. In filter-based instruments the difference is typically negligible.

### 4.4 General Settings for CCD-based instruments:

Please see [www.invitrogen.com/instrumentsetup](http://www.invitrogen.com/instrumentsetup) and click on "ViewLux™" for a step-by-step guide to optimizing LanthaScreen® Terbium assays on the PerkinElmer ViewLux™.

## 5. Guidelines and Recommendations

### 5.1 Reagent Handling

#### **PXR-LBD, GST**

Store the GST tagged PXR-LBD at  $-80^{\circ}\text{C}$ . Thaw on ice before use and perform all dilutions while on ice. Mix by gentle pipetting or inversion of the tube. Never vortex the PXR-LBD stock or dilutions. We recommend aliquoting the PXR-LBD after the first thaw for subsequent experiments.

#### **TR-FRET PXR (SXR) Assay Buffer**

Thaw PXR (SXR) Assay Buffer upon receipt and store at room temperature. Mix well before first use, as the buffer may not have thawed evenly.

#### **LanthaScreen® Tb anti-GST Antibody**

Store Tb anti-GST antibody at  $-20^{\circ}\text{C}$  and thaw before use.

**Important:** To help minimize the potential effect of spurious (random) donor emission spikes in your assay readout, centrifuge the stock vial of Tb anti-GST Antibody (~10,000 rpm for 10 min) prior to use. After centrifugation, pipet the quantity of antibody needed for your assays from the top of the liquid, thereby minimizing the potential mixing of any precipitate that has been spun to the bottom of the tube.

For Technical Support for this or other Drug Discovery Products, dial 760-603-7200 extension 40266

For information on frequently asked questions regarding the LanthaScreen® technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)

### Fluormone™ PXR (SXR) Green

Store Fluormone™ PXR (SXR) Green at  $-80^{\circ}\text{C}$ . Place on ice for at least 15 minutes and then vortex before use. Keep container closed and on ice when not in use to prevent evaporation.

## 5.2 Ligand Dilutions

The procedure described below involves diluting the ligand to 100X in DMSO followed by transfer into complete assay buffer, resulting in a 2X ligand, 2% DMSO dilution. This may be done in a DMSO-tolerant assay plate or tubes such as those made from polypropylene or HDPE. Dilution in DMSO reduces the occurrence of compound precipitation while performing the dilution series, reduces sticking to plastics, improves  $\text{IC}_{50}$  reproducibility and maintains constant DMSO in all wells. After addition of all reagents to the assay, the final concentration will be 1X ligand and 1% DMSO. We suggest using this method for compound dilutions.

**Note:** Handling of some ligands can be problematic due to their tendency to stick to various plastics. These ligands may show varying degrees of stickiness, causing differences in the actual concentration of the ligand, depending on the type of pipette tips and plates used in the set up of the assay. Therefore, you may observe different  $\text{IC}_{50}$  values than reported here.

## 5.3 Solvent Tolerance




Figure 3. Effect of different solvents on assay performance.

The assay was validated in the presence of 1% DMSO. To determine the assay sensitivity to solvents, the assay was performed with up to 8% DMSO, 8% ethanol, or 8% methanol (in addition to the 1% DMSO present from the ligand dilution). The assay window (or signal/background) does decrease at the higher solvent concentrations. Please refer to the graph for details.

## 5.4 Reagent Order of Addition

The assay has been validated using separate tracer and receptor/antibody additions. Use of a premixture containing all three components is not recommended. If the receptor is first allowed to bind to the tracer in the absence of competitor, it is more difficult to displace the tracer from the receptor, and the assay window will be reduced due to a higher background signal. However, the order in which the tracer and receptor/antibody mixtures are added to the assay plate is less critical; the order of addition for these components may be reversed if desired.

For Technical Support for this or other Drug Discovery Products, dial 760-603-7200 extension 40266

For information on frequently asked questions regarding the LanthaScreen® technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)

## 5.5 Incubation Conditions

### Incubation Time

The incubation time can be set by the user. An incubation time of 1–6 hours is recommended. As a guide, sample results (average and standard deviation values) from various incubation time points using SR-12813 as the competitor in at least three independent experiments are shown in the table below.

Incubation Time (hrs)	SR-12813 IC <sub>50</sub> (nM) Avg ± Std dev	Z'-Factor Avg ± Std dev
0.5	73 ± 13	0.81 ± 0.02
1	80 ± 13	0.81 ± 0.02
2	88 ± 15	0.82 ± 0.03
3	95 ± 19	0.81 ± 0.03
4	100 ± 18	0.80 ± 0.04
6	110 ± 21	0.79 ± 0.04
24	140 ± 5	0.71 ± 0.03

### Incubation Temperature

We recommend that assays be conducted at room temperature (20–25°C).

## 6. Procedure

The procedure in this section describes a method for determining the IC<sub>50</sub> of a ligand and the Z' factor for maximum ligand and no ligand controls (n = 24). The only variable is the ligand concentration. All other assay components (PXR-LBD, tracer, Tb anti-GST antibody) are fixed at concentrations optimized to produce a satisfactory assay window (Z'-factor >0.5) while using the lowest receptor concentration to achieve the best sensitivity to tight binding ligands. Assays were measured on a BMG LABTECH PHERAstar fluorescent plate reader. Different plate readers may provide very different assay windows, because the assay window is highly dependent on fluorescent plate reader sensitivity. Higher concentrations of nuclear receptor may give a larger TR-FRET signal window, however it will decrease the sensitivity of the assay with regard to differentiating tight binding ligands. The recommended final concentrations are listed in the following table. If a component concentration is changed, the concentrations of the other components may need to be reoptimized.

Component	Recommended Final Assay Concentrations
Fluormone™ PXR (SXR) Green	40 nM
Tb anti-GST antibody	10 nM
PXR-LBD GST	See Certificate of Analysis for the recommended molar concentration for this kit

### 6.1 Assay Set-Up

**Note:** The PXR-LBD should be thawed on ice just prior to use. During the assay set-up, keep the PXR-LBD and Fluormone™ PXR (SXR) Green on ice. Equilibrate all other assay components to room temperature

#### Prepare Ligand Controls

- For the “no ligand” controls, add DMSO to the TR-FRET PXR (SXR) Assay Buffer for a final concentration of 2% DMSO (2X solvent). Add 10 µL of this buffer containing DMSO to row C, columns 1–24 of a 384-well assay plate (see the plate layout in **Section 6.2**).

For Technical Support for this or other Drug Discovery Products, dial 760-603-7200 extension 40266

For information on frequently asked questions regarding the LanthaScreen® technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)



**Example:** Add 10 µL of DMSO to 490 µL of TR-FRET PXR (SXR) Assay Buffer.

2. Prepare a solution of control ligand (we recommend SR12813) at 100X of the final desired maximum starting concentration using 100% DMSO.

**Example:** If the final desired maximum starting concentration of ligand is 100 µM, prepare a solution of 10 mM ligand in 100% DMSO.

3. For the “maximum ligand” controls, dilute 10 µL of the 100X control ligand solution from Step 2 to 2X using TR-FRET PXR (SXR) Assay Buffer. Add 10 µL of this solution to each well in row D, columns 1–24 in the 384-well assay plate (see the plate layout in **Section 6.2**).

**Example:** Add 10 µL of 100X ligand solution to 490 µL of TR-FRET PXR (SXR) Assay Buffer.

### **Prepare 2X Ligand Dilution Series**

**Note:** Although the steps below require more pipetting than other methods of preparing a serial dilution of ligand, we have found that this approach provides a robust method for preparing the dilution series without problems due to ligand solubility. Dilution with 100% DMSO facilitates compound solubility during serial dilutions, which is important for obtaining consistent IC<sub>50</sub> values.

4. Prepare a 12-point 100X dilution series of ligand in a 96-well polypropylene plate (DMSO tolerant) by serially diluting the 100X ligand solution from Step 2 using 100% DMSO. We recommend a 3-fold dilution series.

**Example:** Add 20 µL of 100% DMSO to wells A2–A12 in a 96-well polypropylene plate. To well A1, add 30 µL of the 100X ligand solution prepared in step 3. Perform a three-fold serial dilution by transferring 10 µL of the 100X ligand solution from well A1 to the 20 µL of DMSO in well A2. Mix by pipetting up and down. Repeat for wells A2–A12.

5. Dilute each 100X agonist serial dilution from Step 4 to 2X using TR-FRET PXR (SXR) Assay Buffer.

**Example:** Transfer 5 µL of each of the 100X agonist serial dilutions from row A of the 96-well plate (wells A1–A12) to row B (wells B1–B12). Add 245 µL of TR-FRET PXR (SXR) Assay Buffer to each well in row B of the 96-well plate. Mix by pipetting up and down.

6. To assay four replicates of each ligand concentration, transfer 10 µL of each of the 2X ligand serial dilutions to the 384-well assay plate according to the plate layout in **Section 6.2**

**Example:** Using a 12-channel pipette transfer 10 µL aliquots from row B of the 96-well plate to alternate columns across row A of the 384 well plate, A1, A3, A5, A7, etc. Continue this process for Row A, this time pipetting into A2, A4, A6, etc. Repeat this process for row B of the 384-well plate.

Alternatively, use a 16-channel pipette where two tips fit into one well of the 96-well plate, then transfer to individual wells of the 384-well assay plate in rows A and B. Repeat to complete all of the columns (1-24).

With either method, wells A1, A2, B1, and B2 all contain the highest concentration of ligand from B1 of the 96-well plate. Wells A3, A4, B3, and B4 all contain the next concentration of ligand from B2 of the 96-well plate, etc. for 4 replicates of each concentration with constant percent DMSO.

### **Prepare 4X Fluormone™ ES2 Green**

7. Prepare 4X Fluormone™ PXR (SXR) Green (160 nM) using TR-FRET PXR (SXR) Assay Buffer.

**Example:** The Fluormone™ PXR (SXR) Green has a stock concentration of 4000 nM and the recommended concentration for this kit is 40 nM, so prepare a 4X solution at 160 nM by adding 40 µL of Fluormone™ PXR (SXR) Green stock to 960 µL of TR-FRET PXR (SXR) Assay Buffer.

8. Add 5 µL of 4X Fluormone™ PXR (SXR) Green to rows A–D, columns 1–24 of the 384-well assay plate. We recommend adding from low to high concentration of ligand (right to left) to prevent ligand carry over.

**For Technical Support for this or other Drug Discovery Products, dial 760-603-7200 extension 40266**

For information on frequently asked questions regarding the LanthaScreen® technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)

### Prepare 4X PXR-LBD(GST)/DTT/4X Tb anti-GST Antibody

**Note:** The volumes in the following steps will depend on the stock concentration and recommended 1X concentration of the PXR-LBD supplied in your specific kit, which are listed on the Certificate of Analysis (CofA).

- Add DTT to a portion of the TR-FRET PXR (SXR) Assay Buffer for a concentration of 0.2 mM. You may want to first make an intermediate dilution of the supplied 1 M DTT to a concentration of 0.1 M in assay buffer.
- Mix by inversion. Based on the stock concentration of Tb-anti-GST antibody (listed on the vial and CofA), add Tb-anti-GST antibody to this solution at a final concentration of 40 nM (4X) (0.5 mg/mL = ~3.4 μM antibody).
- Add PXR-LBD for a concentration that is 4X the recommended 1X concentration listed on the CofA.
- Mix gently several times by inversion or pipetting. Do not vortex. Keep this solution on ice until needed for use in the assay.

**Example:** Assuming a PXR-LBD stock concentration of 2000 nM and recommended 1X concentration of 10 nM (see the CofA for actual concentrations for your kit), first dilute the 1 M DTT stock by 10 fold to 100 mM, then add 2 μL of 0.1 M DTT to 966 μL of TR-FRET PXR (SXR) Assay Buffer and mix. Next add 11.8 μL of the Tb anti-GST antibody. Then prepare a 4X solution of PXR-LBD at 40 nM by adding 20 μL of PXR-LBD stock.

- Add 5 μL of 4X PXR-LBD/DTT/4X antibody solution to rows A–D, columns 1–24 of the 384-well assay plate (see plate layout in **Section 6.2**).


### Plate Incubation and Reads

- Briefly and gently mix the 384-well plate on a plate shaker and incubate at room temperature protected from light for the chosen equilibration time. The plate may be sealed with a cover to minimize evaporation.

**Note:** When using assay plates that are not coated (such as Corning 3677), drops may cling to the side of the wells during additions to the plate. It is critical that the plates be gently tapped or centrifuged to ensure that all reagents reach the bottom of the well.

- Read the plate between 1 and 6 hours at your chosen equilibration time at wavelengths of 520 nm and 495 nm, using the instrument settings described in **Section 4**. If using a plate seal, spin the sealed plate in a centrifuge with an appropriate balance to spin down any condensation on the bottom of the seal, shake the plate gently, and read. Then proceed to data analysis as described in the next section.

## 6.2 Plate Layout



## 6.3 Data Analysis

Calculate the TR-FRET ratio by dividing the emission signal at 520 nm by the emission signal at 495 nm. Generate a binding curve by plotting the emission ratio vs. the log [ligand]. To determine the IC<sub>50</sub> value, fit the data using

**For Technical Support for this or other Drug Discovery Products, dial 760-603-7200 extension 40266**

For information on frequently asked questions regarding the LanthaScreen® technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)

an equation for a sigmoidal dose response (variable slope), as provided by GraphPad™ Prism® 4.0 or another comparable graphing program.

The “maximum ligand” and “no ligand” control data can be used to calculate Z'-factor based on the equation of Zhang *et al* (Zhang *et al.*, 1999).

## 6.4 Reagent Volumes and Controls

The following table summarizes the reagent volumes, order of addition, and recommended controls for the assay. The protocol in Section 6.1 may be adapted to screen test compounds using the following summary table as a guide.

Assay Condition	Reagent Additions	Purpose
Test Compound	1. 10µL 2X Test Compound 2. 5 µL 4X Fluormone™ PXR (SXR) Green 3. 5 µL 4X PXR-LBD/DTT/Tb-anti-GST Ab	Assess competition by test compound of interest using a single concentration or dilution series.
Positive Control	1. 10 µL 2X Control Competitor 2. 5 µL 4X Fluormone™ PXR (SXR) Green 3. 5 µL 4X PXR-LBD/DTT/Tb-anti-GST Ab	Represents 100% tracer displacement (minimum TR-FRET ratio) by a known PXR ligand. We recommend using 1 µM SR12813 as the Control Competitor.
Negative Control	1. 10 µL 2X Test Compound Solvent 2. 5 µL 4X Fluormone™ PXR (SXR) Green 3. 5 µL 4X PXR-LBD/DTT/Tb-anti-GST Ab	Represents 0% tracer displacement (maximum TR-FRET ratio) and accounts for possible interference from a compound's vehicle solvent
No Receptor Control (Optional)	1. 10 µL 2X Test Compound Solvent 2. 5 µL 4X Fluormone™ PXR (SXR) Green 3. 5 µL 4X DTT/Tb-anti-GST Ab	Provides absolute minimum TR-FRET ratio possible, where only non-specific, diffusion-enhanced FRET between the antibody and Fluormone™ is detected.*

**Note:** All controls should contain the same percentage of solvent as the wells containing test compound.


\* Diffusion enhanced TR-FRET occurs when the donor (Tb-anti-GST Antibody) passes by the acceptor (ES2 Green) in solution during the excited state lifetime of the donor and is not related to a binding event. At higher concentrations of donor or acceptor, the probability of this occurrence increases and results in a larger background signal due to diffusion enhanced TR-FRET. The concentrations of ES2 Green used in this assay would result in minimal diffusion enhanced TR-FRET.

For Technical Support for this or other Drug Discovery Products, dial 760-603-7200 extension 40266


For information on frequently asked questions regarding the LanthaScreen® technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)

## 7. Assay Pharmacology

4A.



4B.



**Figure 4: Relative IC<sub>50</sub> Values of Selected Ligands for PXR-LBD in the LanthaScreen® TR-FRET PXR Competitive Binding Assay.** Serial dilutions of various test compounds (1% final DMSO concentration) were assayed (n = 4). Curves were fit using a sigmoidal dose-response equation (variable slope) in GraphPad™ Prism® 4.0. Figures 4A and 4B are the same data plotted differently. The values plotted in 4B have been normalized by the minimum TR-FRET ratio obtained for SR-12813 so that the emission ratio for SR-12813 starts at 1.0. There is no effect on the Z' or calculated IC<sub>50</sub> values.

For Technical Support for this or other Drug Discovery Products, dial 760-603-7200 extension 40266

For information on frequently asked questions regarding the LanthaScreen® technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)

## 8. References

---

Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. *J. Biomol. Screen.*, 4, 67-73

## 9. Notice to Purchaser

---

### **Limited Use Label License No: 168 Lanthanide Chelates**

This product is the subject of U.S. Patent No. 5,622,821, 5,639,615 and 5,656,433 and foreign equivalents licensed exclusively to Invitrogen Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) to not transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use, or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

The performance of this product is guaranteed for six months from the date of purchase if stored and handled properly.

The trademarks mentioned herein are the property of Life Technologies Corporation or their respective owners.

©2010 Life Technologies Corporation. All rights reserved. Reproduction without permission forbidden.

**For Technical Support for this or other Drug Discovery Products, dial 760-603-7200 extension 40266**

For information on frequently asked questions regarding the LanthaScreen® technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)